[Pharmacological treatment of gastroenteropancreatic apudomas with an analog of somatostatin, SMS 201-995 (octreotide)].
Ten patients with gastro-pancreatic apudomas were prospectively treated with SMS 201-995 at the dose of 25-50 mg/12 h. subcutaneously before breakfast and dinner during two months. The biological and clinical effects were evaluated, as well its possible antitumoral action. When clinical or biological benefit was ascertained, the treatment was continued uninterruptedly. SMS 201-995 was well tolerated. It allows ambulatory treatment. It reduced hormonal levels in 62% of cases and controlled symptoms in 50%. No antitumoral effects were observed in the majority of patients.
Varas Lorenzo
M J
MJ
Hospital Cruz Roja, Barcelona.
D000368:Aged; D001079:Apudoma / Q000188:drug therapy*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D011446:Prospective Studies
D015282:Octreotide
Tratamiento farmacológico de los apudomas gastroenteropancreáticos con el análogo de la somatostatina SMS 201-995 (octreotide).